Wyeth (JOBS) Ups Earnings Target After 13% Profit Rise

2009 Second Quarter Reported Diluted Earnings per Share Increased 13% to $0.94, and Diluted Earnings per Share, Excluding Certain Significant Items, Increased 8% to $0.98 - Worldwide Net Revenue Decreased 4% for the 2009 Second Quarter and Increased 2%, Excluding the Impact of Foreign Exchange, Driven by Increases of 24% for Prevnar, 21% for Enbrel (outside the U.S. and Canada) and 9% for Nutritionals - Guidance for the 2009 Full Year Diluted Earnings per Share, Excluding Certain Significant Items, Raised to a Range of $3.48 to $3.58 - Wyeth Stockholders Approve Merger with Pfizer; 98% of Votes Cast in Favor of Merger; Closing Expected at the End of the Third Quarter or during the Fourth Quarter of 2009.

MADISON, N.J., July 23 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE - News) today reported results for the 2009 second quarter and first half ended June 30, 2009. Worldwide net revenue decreased 4% to $5.7 billion for the 2009 second quarter and decreased 5% to $11.1 billion for the 2009 first half. Excluding the unfavorable impact of foreign exchange, worldwide net revenue increased 2% for the 2009 second quarter and first half.